GAMBACORTI PASSERINI CARLO

Duca, F., Manghisi, B., Palasciano, A., Mochi, A., Parma, M., Greco, R., et al. (2026). DNMT3A Co-Mutation and Real-World Clinical Outcomes With Gilteritinib in FLT3-Mutated Acute Myeloid Leukaemia Across Molecular Subgroups. EJHAEM, 7(4) [10.1002/jha2.70374]. Dettaglio

Civettini, I., Malighetti, F., Villa, M., Crippa, V., Aroldi, A., Cavalca, F., et al. (2026). Prognostic Score for Myelodysplastic Syndromes Based on Molecular Evolution. NEJM EVIDENCE, 5(6), 1-13 [10.1056/evidoa2500124]. Dettaglio

Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2025). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED, 6(4) [10.1016/j.medj.2024.11.007]. Dettaglio

Frustaci, A., Zappaterra, A., Turri, G., Rossi, V., Deodato, M., Gambacorti‐passerini, C., et al. (2025). Pirtobrutinib is an Effective Salvage Treatment After Ibrutinib in Bing–Neel Syndrome. AMERICAN JOURNAL OF HEMATOLOGY, 100(10), 1878-1881 [10.1002/ajh.27759]. Dettaglio

Manghisi, B., Cotilli, G., Fedele, M., Perfetti, P., Terruzzi, E., Verga, L., et al. (2025). Case Report: Successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy. FRONTIERS IN IMMUNOLOGY, 16 [10.3389/fimmu.2025.1563736]. Dettaglio